DGAT1 and metabolic dysfunction-associated steatotic liver disease: Specifically, genetic deletion or pharmacological DGAT1 and DGAT2 inhibition reduced hepatic steatosis and hypertriglyceridemia in murine models and MASLD patients (NCT01811472) [19,20,21,22,23,26].